PIMS vs PGT-A in Infertile PCOS Patients

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · Mar 15, 2025

Keywords

ClinConnect Summary

No description provided

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Women aged between 20 and 40 years diagnosed with PCOS according to international evidence-based guidline for assessment and management of policystic ovarian syndrome 2018.
• • 2. Women who plan to undergo IVF/ICSI/PGT-A treatment.
• • 3. Women who obtain 2 or more blastocysts that have morphological score of inner cell mass B or A, trophectoderm C or better, and grade 4 or better on Day 5of embryo culture.
• • 4. Culture all the cleavage stage embryos into blastocysts, conduct biopsy on all the blastocysts, and cryopreserve each blastocyst as a single embryo
• • 5. Agree to the thawing and transfer of a single blastocyst.
• • 6. Sign the informed consent form.
• Exclusion Criteria:
• • 1. Women with a uterine cavity abnormality, such as a uterine congenital malformation (uterus unicornate, bicornate, or duplex); untreated uterine septum, submucous myoma, or endometrial polyp(s); or with history of intrauterine adhesions.
• • 2. Women who are indicated and planned to undergo preimplantation genetic testing for structural rearrangements (PGT-SR) or preimplantation genetic testing for monogenic (PGT-M).
• • 3. Women who use donated oocytes or sperm to achieve pregnancy.
• • 4. Women with contraindication for assisted reproductive technology or for pregnancy, such as undiagnosed liver disease or dysfunction (based on serum liver enzyme testing); renal disease or abnormal serum renal function; significant anemia; history of deep venous thrombosis, pulmonary embolus, or cerebrovascular accident; uncontrolled hypertension, known symptomatic heart disease; history of or suspected carcinoma including including cervical carcinoma, endometrial carcinoma, or breast carcinoma; undiagnosed vaginal bleeding and so on.
• • 5. Untreated hydrosalpinx according to ultrasonography test.